1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"ADDF-Harrington Scholar Program for AI-Enabled Drug Discovery Research in Alzheimer Disease and Related Dementias" is currently closed and not accepting applications.
The ADDF-Harrington Scholar Program identifies and accelerates promising drug discovery research for Alzheimer's disease and related dementias, with explicit support for AI/ML-enabled approaches including generative AI for novel drug candidate identification, deep learning for target validation, AI-driven repurposing of approved drugs, and computational platforms for amyloid and tau pathology.
Scholars receive a 2-year grant of $600K plus comprehensive drug development expertise from the Harrington Discovery Institute and ADDF's Drug Development Accelerator. Optional follow-on investment through ADDF's venture arm. Strong fit for academic investigators with promising preclinical leads, AI-enabled drug discovery platforms, or novel computational therapeutic approaches.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Faculty-level investigators at academic institutions, research nonprofits, and academic medical centers worldwide. Must have novel drug discovery research with clear translational pathway. Industry-only applications not eligible but industry partnerships welcomed. Confirm the full requirements in the official notice before applying.
The current listing shows USD 600,000 over 2 years per scholar plus comprehensive drug development support valued at additional USD 700,000-1,000,000. Total package approximately USD 1,300,000-1,600,000 per awardee. Up to 5 scholars selected per cycle. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was August 15, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
ADDF-Harrington Scholar Program for AI-Enabled Drug Discovery Research in Alzheimer Disease and Related Dementias is funded by Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Schmidt Sciences' AI Impact on Jobs program supports rigorous interdisciplinary research on how generative AI and AI agents are reshaping employment, occupational tasks, wages, productivity, and labor markets. Funded scope includes empirical measurement of AI adoption across industries and occupations, task-level analyses of AI capabilities and displacement, longitudinal studies of worker outcomes, AI's effects on inequality and labor market polarization, evaluation of reskilling and transition programs, AI's role in entrepreneurship and small business productivity, and policy-relevant work on social safety nets and labor regulation in an AI economy.
Path to a Cure Research Grant is a grant from Cystic Fibrosis Foundation that funds basic science research aimed at restoring CFTR protein function or developing gene-based approaches to treat cystic fibrosis. The program specifically targets projects proposing restoration of CFTR protein function or approaches to fix or replace the defective CFTR gene. Awards provide up to $150,000 per year (plus 12% indirect costs) for up to two years, with grants competitively renewable for additional funding. Eligible applicants are independent investigators at for-profit and nonprofit institutions. Proposals must be hypothesis-driven with sufficient preliminary data. The fall cycle deadline is November 15, 2026.
DARPA's DIAL program already had AI rediscover the Kalman filter and wavelets from scratch. SPEED DIAL (DPA26TZ05-DV003) funds the unglamorous next step: turning algorithm discovery into a tool that plugs into MATLAB, Simulink, and COMSOL. Up to $750,000 base plus a $1.25 million option, Direct to Phase II only, with a three-accomplishment feasibility gate and a mandatory university partner. Here is the milestone schedule, the interpretability requirement, and who is actually eligible.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleThe full ASPECT NOFO (DE-FOA-0003647) posted September 4, 2026, eleven days later than the Notice of Intent predicted. The real document splits $58 million across two topic areas with anticipated award counts of 0-7 and 0-3, a cost share that jumps from 20 percent to 50 percent mid-project, a mandatory five-page concept paper due October 9, and a university eligibility restriction that decides team structure before anyone writes a word.
Read article